Company: ENTXW
Filing Date: 2025-06-05
Form Type: DEF 14A
Source: 0001178913-25-002111
Chunk: 52

Company: Entera Bio Ltd.
Filing Date: 2025-06-05
Form: DEF 14A
Chunk 52
---
 the total outstanding shares as of January 1, 2025, became available for issuance under the 2018 Plan. As of January 1, 2025, a total of 4,009,815 Ordinary Shares representing 10% of the total outstanding shares as of that date remained available for issuance under the 2018 Plan. Entera Bio Ltd. | 2025 Annual Meeting Proxy Statement 30

Equity incentive awards may be granted to our employees, non-employee directors, consultants or other advisors, as well as holders of equity compensation awards granted by a company that may be acquired by us in the future. Awards under the 2018 Plan may be granted in the form of options, share appreciation rights, restricted shares, restricted share units, performance awards or other share-based awards. Options and share appreciation rights will have an exercise price determined by the administrator but that is no less than fair market value of the underlying Ordinary Shares on the date of grant. As of December 31, 2024, 6,842,103 Ordinary Shares were issuable upon the exercise of outstanding options under the 2018 Plan, at a weighted-average exercise price of $1.91 per share. Of the foregoing outstanding awards, as of December 31, 2024, options to purchase 4,183,659 Ordinary Shares, in the aggregate, had vested under the 2018 Plan, with a weighted-average exercise price of $2.05 per share. In addition, as of December 31, 2024, 104,775 Ordinary Shares are issuable upon the vesting of outstanding RSUs under the 2018 Plan. The vesting conditions for grants under the 2018 Plan will be determined by the administrator and, in the case of restricted shares and restricted share units, will be set forth in the applicable award documentation. In the event of a participant’s termination of employment, the administrator may, in its discretion, determine the extent to which an equity incentive award may be exercised, settled, vested, paid or forfeited. In the event of a “Change in Control” (as defined in the 2018 Plan) of the Company, the Compensation Committee may, in its discretion, take a number of actions with respect to awards outstanding under the 2018 Plan, including the following: (i) continuing awards or converting such awards into an award or right with respect to shares of the successor or surviving corporation; (ii) immediately vesting and settling awards (or in the